Start-up company ImmuVen and the University of Illinois Urbana-Champaign have entered into a license agreement under which ImmuVen will develop modified T cell receptor proteins for the purpose of treating cancer and methicillin-resistant Staphylococcus aureus (MRSA). ImmuVen was co-founded by Dr. David Kranz of the University of Illinois Urbana-Champaign and Dr. Patrick Schlievert of the University of Minnesota.
ImmuVens technology focuses on the engineering of T cell receptor proteins for treatments in which classical drugs have proven unsuccessful. T cell receptors can be found on the surface of T cells, one of the major types of white blood cells involved in fighting diseases. They have many features similar to antibodies including the recognition of foreign antigens.
Unlike classical treatments for MRSA, ImmuVens T cell receptor proteins work by targeting the toxins rather than destroying the foreign organism. ImmuVen took this approach because once the toxins are released into a persons bloodstream, the person will remain sick even after the organism releasing the toxins is killed. For this reason, ImmuVen engineered a T cell receptor protein that binds to and neutralizes the toxins, thereby preventing their toxicity.
Currently ImmuVen is one of only a few companies looking at this approach for treating MRSA, a drug-resistant staph infection responsible for more than 18,000 deaths in children and adults each year. To date, modified T cell receptors have been successful in treating MRSA in animal studies performed at the University of Minnesota.
In addition to treating MRSA, ImmuVen is also engineering T cell receptor proteins that could be effective therapeutics for cancer. Researchers plan to remove the T cell receptor from the patient, engineer it to better target the cancer, and deliver back to the patient. ImmuVen is currently developing strategies to both improve and deliver the T cell receptors.
According to ImmuVen Interim CEO, Tim Hoerr, the next steps for ImmuVen include submission of an Investigational New Drug (IND) application to the FDA and continued development of several key leads against MRSA and specific types of cancers. Hoerr realizes how critical this license was to the growth of ImmuVen and is pleased with the efficiency of the licensing process between ImmuVen and the university.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.